This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): labetuzumab-I-131, hCEA-I-131
Description: IMMU-111 is an I-131-labeled carcinoembryonic antigen (CEA) antibody. The CEA antigen is abundant at the site of virtually all cancers of the colon and rectum, and is associated with many other solid tumors, such as breast and lung cancers.
Pink Sheet FDA Performance Tracker: User Fee Goal Dates
Additional information available to subscribers only: